Spin-off Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies
07-Jul-2021 -
Scailyte, a single-cell biomarker discovery spin-off of ETH Zurich and Lexogen, a leader in RNA sequencing solutions, announce a strategic partnership. The companies will create a joint biomarker discovery workflow, leveraging Lexogen’s new single-cell RNA sequencing platform LUTHOR™ and ...
biomarkers
precision medicine